Sorangicin A Is Active against <i>Chlamydia</i> in Cell Culture, Explanted Fallopian Tubes, and Topical In Vivo Treatment

Current treatment of <i>Chlamydia trachomatis</i> using doxycycline and azithromycin introduces detrimental side effects on the host’s microbiota. As a potential alternative treatment, the myxobacterial natural product sorangicin A (SorA) blocks the bacterial RNA polymerase. In this study we analyze...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Simon Graspeuntner, Katharina Koethke, Celeste Scholz, Lea Semmler, Mariia Lupatsii, Laura Kirchhoff, Jennifer Herrmann, Katharina Rox, Kathrin Wittstein, Nadja Käding, Lars C. Hanker, Marc Stadler, Mark Brönstrup, Rolf Müller, Kensuke Shima, Jan Rupp
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	MDPI AG 2023-04-01
Rangatū:	Antibiotics
Ngā marau:	sorangicin A antibiotics <i>Chlamydia trachomatis</i> <i>Chlamydia muridarum</i> mouse novel therapeutics
Urunga tuihono:	https://www.mdpi.com/2079-6382/12/5/795
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!